Allurion, Minogue Medical Team Up on Obesity Management

Allurion Technologies Inc. has negotiated a strategic distribution partnership with Minogue Medical Inc. to establish a new standard of care in obesity management focused on metabolically healthy weight loss.

Minogue Medical has four decades of experience building high-performing medical networks across Canada. With a national ecosystem of dietitians, bariatric surgeons, and endoscopic specialists, the company ensures every patient journey is supported by highly qualified professionals who deliver a comprehensive program.

“We select partners who share our vision for ethical, patient-centered care,” Minogue Medical CEO Danny Minogue stated. “Allurion’s commitment to clinical rigor complements our approach, and together, we intend to set a new benchmark in Canadian weight management.”

Allurion is pioneering metabolically healthy weight loss, a new approach to obesity care focused on losing weight, keeping it off, and maintaining muscle. In partnership with Minogue Medical, Allurion will now be able to access providers who are committed to this approach and have demonstrated good clinical results. In addition, the partnership is expected to increase access to providers offering a combination of the Allurion Program with GLP-1 therapy, to further enhance short and long-term results.

“Minogue Medical has built a strong reputation in Canada for its deep clinical expertise, strong network, and a proven ability to bring meaningful innovations to the field of metabolic and bariatric care,” said Dr. Michel Gagner, a Canadian bariatric surgeon. “Their multidisciplinary approach—engaging dietitians, surgeons, and endoscopists alike—ensures that patients are treated within a medically supervised, evidence-based framework. I am confident that this partnership represents a pivotal step forward for obesity care in Canada.”

“This agreement with Minogue Medical reflects our commitment to find partners globally who believe in our approach to obesity care,” Allurion Founder/CEO Dr. Shantanu Gaur commented. “We are looking forward to working with Minogue to develop the Canadian market and establish a new standard of care in the treatment of obesity.”

Minogue Medical is a Montreal-based medical device distributor specializing in bariatric and obesity care. With a focus on ethical integration, clinician training, and long-term care pathways, Minogue supports a national network of medical professionals in delivering high-quality, patient-centered care.

Allurion’s weight-loss platform combines the Allurion Gastric Balloon, the world’s first and only swallowable, Procedureless gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.